Swixx BioPharma

Swixx BioPharma is designed to fully replace biopharma, OTC and medical device multinationals’ subsidiaries or business units in those countries, or therapeutic areas of CEE, that the multinational chooses not to enter, or to exit

Farmak International

Farmak International: Providing high-quality pharmaceutical products promptly and precisely where they are needed in ~60 countries around the world

Bachem

The Swiss-based Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides. With over 50 years of experience and expertise Bachem provides products for research, clinical development and commercial application to pharmaceutical and biotechnology companies worldwide and offers a comprehensive range of services. Bachem operates internationally with headquarters in Switzerland and locations in Europe, the US and Asia.

IBSA Group

IBSA Institut Biochimique SA is a privately owned pharmaceutical company founded in Lugano in 1945. It started to develop its specific identity in 1985, when the current management took over, redefining its strategy and focusing on developing technologies that improve the quality of existing therapeutic solutions. Today, it is present on 5 continents and over 90 countries. The Group now counts on 20 subsidiaries in Europe, China and USA, and boasts a product portfolio covering 10 therapeutic areas. The company employs over 2,300 people, distributed among its headquarters, subsidiaries and manufacturing sites. IBSA is one of the four largest operators worldwide in the area of Reproductive Medicine and one of the world's leaders in hyaluronic acid-based products. Therapeutic areas: 🔹 Reproductive Medicine 🔹 Endocrinology 🔹 Pain and Inflammation 🔹 Osteoarticular 🔹 Aesthetic Medicine 🔹 Dermatology 🔹 Uro-gynaecology 🔹 Cardiometabolic 🔹 Respiratory 🔹 Consumer Health

PSI CRO AG

PSI is a leading full-service global Contract Research Organization whose key strength is predictable patient enrollment across multiple therapeutic areas. PSI is known in the industry as a CRO focused on ‘on-time project delivery’. This is achieved through investing substantial effort and MD resources into performing quality feasibility assessments that provide an accurate predictor of study timelines. PSI’s global reach allows us to run clinical trials across multiple continents, in 50+ countries around the world. PSI’s reputation is that of a 'no-nonsense'​ CRO focused on timely patient enrollment and project delivery. An exceptionally high repeat and referral business rates alongside low staff turnover are indicative of our commitment to be the best CRO in the world as measured by our clients and our employees. http://www.psi-cro.com